Kyverna Therapeutics (KYTX) Equity Average (2023 - 2026)
Kyverna Therapeutics posted quarterly Equity Average of $213.9 million for Q1 2026, down 12.79% year-on-year from $245.3 million in Q1 2025, and up 11.36% on a QoQ basis from $192.1 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Equity Average data on file, last reported at $213.9 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 12.79% year-over-year to $213.9 million; the trailing twelve-month figure through Mar 2026 stood at $213.9 million (down 12.79% YoY), and the FY2025 full-year result was $249.4 million, up 96.83% from the prior year.
- Equity Average for Q1 2026 stood at $213.9 million, up from $192.1 million in the prior quarter.
- Across five years, Equity Average topped out at $347.2 million in Q2 2024 and bottomed at -$104.5 million in Q3 2023.
- The 4-year median for Equity Average is $198.2 million (2025), against an average of $157.5 million.
- The widest annual swing landed in 2024, when Equity Average soared 555.64%; it then sank 47.14% in 2025.
- A 4-year view of Equity Average shows it stood at -$62.5 million in 2023, then jumped by 555.64% to $284.6 million in 2024, then slumped by 32.51% to $192.1 million in 2025, then advanced by 11.36% to $213.9 million in 2026.
- The last three Equity Average figures came in at $213.9 million (Q1 2026), $192.1 million (Q4 2025), and $168.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | 213.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 213.93 Mn |
| Dec 31, 2025 | 192.11 Mn |
| Sep 30, 2025 | 168.16 Mn |
| Jun 30, 2025 | 204.19 Mn |
| Mar 31, 2025 | 245.30 Mn |
| Dec 31, 2024 | 284.65 Mn |
| Sep 30, 2024 | 318.11 Mn |
| Jun 30, 2024 | 347.25 Mn |
| Mar 31, 2024 | 173.93 Mn |
| Dec 31, 2023 | -62.47 Mn |
| Sep 30, 2023 | -104.50 Mn |
| Jun 30, 2023 | -90.90 Mn |